Franklin Street Advisors Inc. NC Decreases Position in Kenvue Inc. (NYSE:KVUE)

Franklin Street Advisors Inc. NC decreased its position in Kenvue Inc. (NYSE:KVUE) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 204,082 shares of the company’s stock after selling 6,515 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Kenvue were worth $4,380,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of KVUE. Vanguard Group Inc. lifted its position in Kenvue by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 148,880,588 shares of the company’s stock valued at $3,205,399,000 after purchasing an additional 2,226,390 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Kenvue by 19.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 109,327,221 shares of the company’s stock valued at $2,353,816,000 after buying an additional 18,118,056 shares during the last quarter. Wellington Management Group LLP increased its holdings in Kenvue by 6.7% during the fourth quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock valued at $1,647,087,000 after buying an additional 4,815,126 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Kenvue by 9.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 66,665,454 shares of the company’s stock valued at $1,435,307,000 after buying an additional 5,574,265 shares during the last quarter. Finally, Morgan Stanley increased its holdings in Kenvue by 4,057.4% during the third quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock valued at $625,745,000 after buying an additional 30,413,040 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on KVUE shares. Citigroup reissued a “neutral” rating and issued a $21.00 price objective on shares of Kenvue in a research note on Tuesday, May 28th. William Blair initiated coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. HSBC upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $23.09.

Kenvue Stock Down 0.7 %

Shares of Kenvue stock traded down $0.13 on Thursday, reaching $18.46. The stock had a trading volume of 6,169,746 shares, compared to its average volume of 19,196,590. The company has a 50 day moving average price of $19.24 and a 200 day moving average price of $20.01. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1 year low of $17.75 and a 1 year high of $26.66. The stock has a market capitalization of $35.35 billion and a P/E ratio of 23.83.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. The business’s revenue was down 24.9% on a year-over-year basis. As a group, equities research analysts forecast that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 4.33%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s dividend payout ratio (DPR) is presently 102.56%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.